Dendritic cell (DC) homeostasis, like all mature blood cells, is maintained via hierarchal generation from hematopoietic precursors; however, little is known about the regulatory mechanisms governing DC generation. Here we show that prostaglandin E 2 (PGE 2 ) is required for optimal Flt3-ligand-mediated DC development and regulates expression of the Flt3 receptor on DC-committed progenitor cells. Inhibition of PGE 2 biosynthesis reduces Flt3-mediated activation of STAT3 and expression of the anti-apoptotic protein Survivin, resulting in increased apoptosis of DC-committed progenitor cells. Reduced DC development caused by diminished PGE 2 signaling is reversed by over expression of Flt3 or Survivin in DC progenitors and conversely is mimicked by STAT3 inhibition. PGE 2 regulation of DC generation is specifically mediated through the EP1 and EP3 G-protein PGE 2 receptors. These studies define a novel DC progenitor regulatory pathway where PGE 2 signaling through EP1/EP3 receptors regulates Flt3 expression and downstream STAT3 activation and Survivin expression, required for optimal DC progenitor survival and DC development in vivo.
INTRODUCTION
Dendritic cells (DCs) are specialized antigen-presenting immune cells that induce adaptive immune responses and maintain self-tolerance and are attractive targets for therapeutic manipulation of the immune system 1, 2 . Two main DC subsets have been identified based on their location, phenotype and function; antigen-presenting classical DC (cDC), and type I interferon-producing plasmacytoid DC (pDC) 3, 4 , and are generated from Flt3-expressing hematopoietic progenitor cells in the bone marrow (BM) 5, 6 . Recent studies identified a common DC, monocyte and macrophage precursor designated as macrophage DC progenitor cell (MDP) 7, 8 and a common DC progenitor (CDP) that is restricted to DC development 9 . MDP differentiate to CDP, which in turn give rise to cDC and pDC, but not monocyte, and finally to pre-cDC 10 , a committed precursor of cDCs 11, 12 . Unlike MDP and CDP that differentiate within the BM, precDCs traffic to secondary lymphoid organs where they further differentiate into cDC 4, 13 . In addition, monocytes can also develop a DC phenotype under inflammatory conditions 14, 15 .
Flt3 (also known as Flk2 and CD135) is a receptor tyrosine kinase that is broadly expressed on early BM hematopoietic progenitor cells (HPC), including DC progenitor cells 5, 9, 16 . Mice with a deficiency in Flt3 or Flt3 ligand (Flt3L) have reduced DC numbers 13, 17 , whereas administration of Flt3L dramatically increases BM and peripheral DC 18 . While Flt3 signaling is crucial for DC generation from their progenitor cells at steady-state, the normal physiological mechanisms that control Flt3 expression and regulate Flt3L-dependent DC differentiation remain poorly understood.
Prostaglandin E 2 (PGE 2 ) is the predominant metabolite of arachidonic acid metabolism produced through the sequential action of phospholipase A 2 , cyclooxygenases and prostaglandin
For personal use only. on April 10, 2017 . by guest www.bloodjournal.org From 4 4 E synthase 19, 20 . There are two functionally distinct cyclooxygenase (COX) enzyme isoforms, COX1 and COX2 that are encoded by different genes 20 . PGE 2 has been shown to modulate HPC differentiation, inhibiting CFU-GM [21] [22] [23] but promoting BFU-E and CFU-GEMM 24, 25 . The longacting PGE 2 analog, 16,16-dimethyl-PGE 2 (dmPGE 2 ) was shown to increase hematopoietic stem cell (HSC) frequency and engraftment 26, 27 and enhances HSC survival, proliferation and homing to the BM 27 . Thus, PGE 2 regulates self-renewal and differentiation of HSC and HPC and its effects can differ depending on hematopoietic cell type and stage of differentiation.
The role of PGE 2 in DC maturation and migration under inflammatory conditions is well known. PGE 2 promotes the migration of monocyte-derived and Langerhans DCs, increases their expression of costimulatory molecules, and enhances their ability to stimulate T cells after exposure to proinflammatory cytokines and antigens [28] [29] [30] . However, the role of PGE 2 in regulation of DC differentiation from their specific progenitor cells and maintenance of DC homeostasis at steady state has not been explored. We now report that PGE 2 is an important regulator of Flt3L-dependent DC development. PGE 2 regulates DC development by modulating
Flt3 expression on DC-committed progenitor cells, resulting in increased STAT3-mediated
Survivin expression that enhances survival of DC-committed progenitor cells. The effect of PGE 2 on DC progenitor cells is specifically mediated via signaling through the EP1 and EP3 Gprotein coupled PGE 2 receptors and DC production was significantly lower in EP1, EP3 and EP1/EP3 knockout mice. Our results are the first to define a role of PGE 2 in normal Flt3L-dependent DC differentiation and describe a novel regulatory pathway for DC generation that can be pharmaceutically manipulated.
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Inhibition of PGE 2 synthesis
Mice were injected subcutaneously (s.c.) with Indomethacin (2.5 mg/kg/bid) ( complete medium (10% FBS) with 10 ng/ml recombinant mouse granulocyte-macrophagecolony stimulating factor (GM-CSF) to induce DC generation. For DC generation from human UCB, CD34 + cells were purified from low density UCB using CD34 antibody conjugatedmagnetic beads (Miltenyi Biotech) and cultured for 10 days in Flt3L (100 ng/ml), stem cell factor (50 ng/ml), IL-3 (10 ng/ml) and IL-6 (10 ng/ml) supplemented STEM Pro-CD34
(Invitrogen) medium as described 31 in the presence or absence of Indomethacin.
Cell sorting and flow-cytometry analysis
BM and spleen were harvested and single cell suspensions prepared in IMDM with 2% FBS.
Total nucleated cell counts were obtained using a 10 . Surface Flt3 expression on CDP and pre-cDC gated cell population was determined by flow-cytometry.
DC progenitor proliferation and survival
Indomethacin or vehicle treated mice were injected with bromodeoxyuridine (BrdU) (1 mg; i.p.).
Mice were sacrificed 20 hours after BrdU injection and BM cells were harvested and stained with cell surface antibodies for CDP and pre-cDC. Cells were then fixed and permeabilized for Figure S1 ), which is consistent with the increase in CFU-GM we previously reported 33 . The total number of MDPs per femur was not statistically different than control in Indomethacin treated mice, although they did trend lower ( Figure S1B ). These findings expand the scope of regulation of hematopoiesis by PGE 2 to include the DC-committed progenitor cell compartment.
PGE 2 is a positive regulator of Flt3L-dependent DC generation from hematopoietic progenitor cells
At steady-state, DC development is mainly dependent on Flt3 signaling 13, 17, 18 . To evaluate the role PGE 2 plays in DC development from hematopoietic progenitor cells, we evaluated Flt3L-dependent generation of DC from BM cells in vitro. Lineage depleted mouse BM cells enriched for CDP were cultured for 9 days in Flt3L supplemented medium with 12 12 Indomethacin, with or without dmPGE 2 , and DC enumerated by flow cytometry using a previously defined phenotypic determination 9 . Generation of CD11c + B220 -cDC and CD11c + B220 + pDC was substantially reduced in the presence of Indomethacin (cDC: 48±3.1% and pDC:
27±1.4%) ( Figure 2A ). Addition of exogenous PGE 2 completely reversed the Indomethacin mediated reduction in DC differentiation, indicating that PGE 2 signaling is required for optimal DC generation. Consistent with the requirement of PGE 2 for optimal DC generation, PGE 2 levels were virtually absent in cultures grown in the presence of Indomethacin ( Figure 2B ). To test whether endogenous PGE 2 biosynthesis by DC-committed progenitor cells directly regulates DC differentiation and to rule out effects mediated through accessory cells, including stromal cells,
we evaluated the effects of PGE 2 inhibition on DC generation from highly purified DC progenitors. Bone marrow CDP were FACS sorted (>98% purity) and cultured for 9 days in Flt3L-supplemented media with or without Indomethacin. Significantly fewer DC were generated from purified CDP in the presence of Indomethacin compared to control ( Figure 2C ) strongly suggesting autocrine secretion.
To determine the COX enzyme involved in PGE 2 biosynthesis by DC-committed progenitor cells, we induced Flt3L-dependent DC differentiation in vitro in the presence of a selective COX1 (SC560) or COX2 (NS-398) inhibitor. The COX2 specific inhibitor NS-398 substantially reduced DC generation equivalent to that observed with Indomethacin, while the COX1 selective inhibitor, SC560, was substantially less effective ( Figure 2D ), suggesting that PGE 2 production primarily via the COX2 isoform is required for optimal DC generation.
Addition of exogenous PGE 2 during Flt3L-induced DC development, enhanced DC generation particularly at 0.1 and 10 nM ( Figure 2D ) further supporting a role for PGE 2 in DC development.
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Similar to the mouse model, inhibition of PGE 2 synthesis impairs Flt3L, SCF, IL-3 and IL-6 induced CD1a + CD14 -DC progenitor cell generation and CD11c + CD14 -myeloid DC generation from human CD34 + cord blood cells ( Figure 2E ), demonstrating that PGE 2 regulation of DC generation from HPC is conserved across species.
While the numbers of DCs generated in the presence of Indomethacin are reduced, these
DCs do up-regulate MHC-II, CD40 and CD86 upon LPS stimulation to a similar degree compared to DCs generated with Flt3L alone ( Figure S2A ), with no difference in IL-6 or IL-12 cytokine production (Table S1 ). Similarly, DCs generated from Indomethacin-treated C57Bl/6 mice cultured with CFDA-SE labeled CD4 + T cells from BALB/c mice in a mixed lymphocyte reaction (MLR) assay induced a similar level of T cell proliferation compared to control ( Figure   S2B ). These results indicate that while inhibition of PGE 2 signaling during DC development reduces total DC progenitor number and impairs optimal DC generation, those DCs that are produced appear to function normally at least in vitro.
DC differentiation from progenitor cells can also be induced by GM-CSF 35 , although it is not required for in vivo DC development 13 . To determine whether inhibiting PGE 2 biosynthesis exclusively reduces Flt3L-dependent DC development, or globally reduces DC differentiation, we induced mouse DC differentiation with GM-CSF in vitro in the presence or absence of Indomethacin. In contrast to Flt3L-induced DC generation, GM-CSF-mediated DC development was significantly higher after Indomethacin treatment compared to control ( Figure 2F ), indicating that PGE 2 differentially regulates Flt3L-dependent and GM-CSF-dependent DC development.
PGE 2 protects DC progenitors from apoptosis
Attenuated DC generation as a result of reduced PGE 2 signaling could result from a defect in DC-committed progenitor cell survival or as a consequence of effects on DC progenitor cell proliferation. To explore the functional consequences of inhibition of PGE 2 biosynthesis on DC progenitor cell proliferation, we first examined the effect of Indomethacin treatment on BM CDP proliferation. Analysis of Flt3L-stimulated CDP proliferation in vitro was unaffected by Indomethacin ( Figure 3A ). To further explore the effects of PGE 2 biosynthesis inhibition on DC progenitor cell proliferation in vivo, mice were treated with Indomethacin for 6 days and pulsed with BrdU for the last 20 hours prior to sacrifice. BrdU incorporation in CDPs was unchanged after Indomethacin treatment, while the total number of CDPs was decreased as we described ( Figure 3B ). These results demonstrate that reduced PGE 2 signaling does not alter DC progenitor cell proliferation.
To investigate whether impaired DC development after inhibition of PGE 2 biosynthesis resulted from an effect on DC progenitor cell survival, we first evaluated survival of pre-cDC generated from CDP enriched BM cells in the presence of Flt3L plus Indomethacin in vitro. PrecDC survival was significantly reduced, measured by both Annexin-V staining ( Figure 3C ; left panel) and expression of activated caspase-3 ( Figure 3C ; right panel). Analysis of active caspase-3 expression in BM CDP and pre-cDC after treatment of mice with Indomethacin also showed significantly higher levels of active caspase-3 in CDP and pre-cDC of Indomethacin treated mice, consistent with fewer viable CDP and pre-cDC ( Figure 3D ). These data suggest that PGE 2 regulates DC production primarily by attenuating apoptosis thus promoting DC 15 15 progenitor cell survival and are consistent with several studies that indicate that PGE 2 protects many cell types of hematopoietic origin from apoptosis 27, 36 .
PGE 2 regulation of Flt3 expression enhances DC progenitor cell survival via STAT3-mediated elevation in Survivin
STAT3 is a known transcription factor downstream of Flt3 signaling that is required for DC development 37, 38 . PGE 2 has been shown to regulate STAT3 phosphorylation and protect cardiomyocytes from doxorubicin-induced apoptosis 39, 40 . We therefore examined the effect of inhibiting PGE 2 biosynthesis on STAT3 phosphorylation in pre-cDCs generated from Figure 5A ). In contrast, the EP2 specific agonist Butaprost and the EP4 specific agonist L-902,688, failed to rescue DC generation. We also evaluated the ability of EP receptor selective antagonists to inhibit DC development. Antagonism of EP1 receptor signaling with the EP1 specific antagonist SC51322 or EP3 receptor signaling with the EP3 specific antagonist L-798,106 resulted in significantly reduced DC differentiation both in vitro ( Figure   5B , left) and in vivo ( Figure 5B, right) . Consistent with the effect of EP1 and EP3 receptor specific agonists to rescue DC generation when PGE 2 biosynthesis/signaling is inhibited, 17-ptPGE 2 and Sulprostone reversed the Indomethacin-mediated reduction in Survivin in pre-cDC generated from CDP ( Figure 5C ). These data demonstrate that PGE 2 regulates DC differentiation through EP1 and EP3 receptor signaling.
To further validate the involvement of EP1/EP3 signaling in DC development, we evaluated total DC number in EP1 and EP3 receptor single knockout mice and EP1/EP3 double knockout mice. Total DC cell number was significantly lower in the BM and spleen of the EP1 and EP3 receptor single knockout mice compared to wild-type control mice ( Figure 5D ). In addition, double EP1/EP3 receptor knockout mice showed significantly more reduction in DC number in BM and spleen, mimicking results with Indomethacin, and confirming agonist/antagonist data demonstrating a role of both EP1 and EP3 receptors in DC-progenitor cell function. 20 20 fewer DCs after Indomethacin treatment of highly purified CDP cultures, which lack HSC, indicates that PGE 2 regulation of DC differentiation is mediated by direct effects on DCcommitted progenitor cells.
At least two cellular processes, proliferation and apoptosis, can control mature blood cell generation from HPC. In contrast to the effects of PGE 2 on myeloid, erythroid and multipotential progenitor cell proliferation [22] [23] [24] [25] 34 , inhibition of PGE 2 . Since, these pathways are activated by EP1 and EP3 signaling 53, 54 , and our data identified that PGE 2 regulates Flt3L dependent DC development through the EP1 and EP3
receptors, it is possible that PGE 2 mediated induction of PI3K/AKT and Src signaling pathways regulates PU.1 expression in DC-committed progenitors that leads to increased expression of Flt3. However, in other progenitor lineages change in transcription factor activities in the absence of change in expression has been reported 55 . Further study is needed to define the transcriptional events regulating PGE 2 induced Flt3 expression in DC progenitor cells.
Based upon these in vitro and in vivo findings, we propose a model where PGE 2 signaling through the EP1 and EP3 receptors regulates Flt3 expression on DC progenitors. Flt3 receptor signaling activates STAT3 and enhances Survivin expression in DC progenitors, which protects them from apoptosis, resulting in optimal DC generation, and that inhibition of PGE 2 signaling impairs DC generation ( Figure 6 ). Due to its potent antigen presentation properties, DCs are 22 22 required for induction of immune responses at the onset of infection and quantitative and functional loss of DCs has been attributed to severity of infectious diseases 56, 57 . In this context, our studies raise the possibility that NSAIDs inhibiting PGE 2 biosynthesis, particularly when taken over extended periods of time, may exacerbate disease as a consequence of reduced DC generation. In addition, several experimental and clinical studies support the use of DC vaccines 58 ; however, current DC vaccines are not optimal for the treatment of human diseases.
One of the major hurdles for DC vaccine development is a generation of large numbers of DCs that can be used to deliver target antigens to generate anti-tumor or anti-infective immune responses. Understanding DC differentiation mechanisms would be an essential step to achieve this goal. Our study illustrates that physiological doses of PGE 2 are crucial for optimal DC generation and may prove useful for efficient DC generation for vaccine development.
Furthermore, recent studies suggest a role for PGE 2 in self-renewal and expansion of HSC 26, 27 and while the up-regulation of PGE 2 production after total body irradiation 59 may be beneficial for HSC homing, engraftment and expansion in the short term, our studies suggest that prolonged elevated levels of PGE 2 may lead to altered hematopoietic progenitor function and DC generation. Further studies evaluating the regulatory role of PGE 2 in hematopoietic generation of immune cells post-transplant will identify how best to therapeutically modulate PGE 2 signaling during and after hematopoietic transplantation for maximal benefit. 
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